Literature DB >> 31527216

A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor.

Julien Prouvot1,2, Cédric Aglaé1,2, Laurent Daniel3, Olivier Moranne1,2.   

Abstract

A middle-aged woman with history of antiphospholipid syndrome, admitted to our hospital for lethargy and persistent chest pain, developed during hospitalisation intracerebral transverse sinus and sigmoid vein thromboses, retinal thromboses, acute renal failure and cardiac involvement associated with thrombocytopaenia. Diagnosis of catastrophic antiphospholipid syndrome was made and treated with IV steroids, heparin infusion and double filtration plasmapheresis (DFPP) without fresh frozen plasma. Heparin-induced thrombocytopaenia was second diagnosed because of persistent severe thrombocytopaenia after 2 weeks of treatment associated with positive conversion of antibodies against platelet factor 4, and a positive functional assay. The clinical course was complicated by cerebellar haematomas that appeared a few days after the last session of DFPP. Heparin-induced thrombocytopaenia was managed by administration of argatroban, a direct thrombin inhibitor with an increase in platelet count. Neurologically, the patient recovered completely and was discharged on vitamin K antagonist treatment and regular dialysis. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute renal failure; haematology (incl blood transfusion); immunology; venous thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 31527216     DOI: 10.1136/bcr-2019-231161

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

1.  Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia: A case report.

Authors:  Bo Yang; Jing Yang; Lan Zhou; Cheng Xue; Hongxian Li; Weifeng Hu; Nanmei Liu
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.